Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04383210 | Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors | terminated | Phase 2 | 54 | Elevation OncologyINDUSTRY | 4 | Apr 3, 2025 | clinicaltrials |
| NCT06906731 | A Study of SHR-9803 for Injection in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 27 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 2, 2025 | clinicaltrials |
| NCT05269316 | Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 61 | Impact Therapeutics, Inc.INDUSTRY | 4 | Apr 1, 2025 | clinicaltrials |
| NCT05784688 | Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 140 | TiumBio Co., Ltd.INDUSTRY | 2 | Mar 30, 2025 | clinicaltrials |
| NCT05963386 | Clinical Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Various Solid Tumors | completed | Phase 2 | 28 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT04084366 | Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 44 | OBI Pharma, IncINDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06895733 | Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1) | recruiting | Phase 1 / Phase 2 | 65 | Tianjin Medical University Second HospitalOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT04716634 | Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors | completed | Phase 2 | 84 | BeiGeneINDUSTRY | 2 | Mar 25, 2025 | clinicaltrials |
| NCT05146440 | Multicohort Trial of Different Schemes of PM14 in Monotherapy and in Combination with Radiotherapy in Soft Tissue Sarcomas and Other Solid Tumor(PRIME) | recruiting | Phase 1 / Phase 2 | 195 | Grupo Espanol de Investigacion en SarcomasOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT05970016 | A Phase I/II Clinical Study in Patients with Advanced Solid Tumor. | recruiting | Phase 1 / Phase 2 | 56 | Beijing Tide Pharmaceutical Co., LtdINDUSTRY | 1 | Mar 21, 2025 | clinicaltrials |
| NCT06775236 | Clinical Trial of SYS6010±SYH2051 Versus Chemotherapy in Advanced Breast Cancer and Other Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 410 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 0 | Mar 19, 2025 | clinicaltrials |
| NCT04101357 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 | terminated | Phase 1 / Phase 2 | 54 | BioNTech SEINDUSTRY | 4 | Mar 18, 2025 | clinicaltrials |
| NCT04585035 | Study to Evaluate D-1553 in Subjects With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 180 | InventisBio Co., LtdINDUSTRY | 4 | Mar 18, 2025 | clinicaltrials |
| NCT05543629 | A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 36 | Bristol-Myers SquibbINDUSTRY | 5 | Mar 18, 2025 | clinicaltrials |
| NCT02694822 | AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy | completed | Phase 1 / Phase 2 | 89 | Agenus Inc.INDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
| NCT04761198 | A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors | completed | Phase 1 / Phase 2 | 76 | Mereo BioPharmaINDUSTRY | 2 | Mar 17, 2025 | clinicaltrials |
| NCT04907851 | A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2)(KEYNOTE-E86) | completed | Phase 2 | 45 | Redx Pharma LtdINDUSTRY | 2 | Mar 17, 2025 | clinicaltrials |
| NCT06873854 | A Study of LM-108 in Combination With Toripalimab in Subjects With Advanced Solid Tumours | not yet recruiting | Phase 2 | 84 | LaNova Medicines LimitedINDUSTRY | 1 | Mar 13, 2025 | clinicaltrials |
| NCT04172506 | A Study to Evaluate the Efficacy and Safety of Anti-PD-1 Antibody AK105 in Patients With Selected Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 65 | AkesoINDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT05142423 | A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 198 | AkesoINDUSTRY | 1 | Mar 12, 2025 | clinicaltrials |
| NCT04597541 | A Study of AK112 for Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 59 | AkesoINDUSTRY | 1 | Mar 10, 2025 | clinicaltrials |
| NCT05487170 | A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1) | recruiting | Phase 1 / Phase 2 | 32 | Ranok Therapeutics (Hangzhou) Co., Ltd.INDUSTRY | 2 | Mar 4, 2025 | clinicaltrials |
| NCT05126433 | Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors(JAZZ EMERGE201) | terminated | Phase 2 | 47 | Jazz PharmaceuticalsINDUSTRY | 1 | Feb 28, 2025 | clinicaltrials |
| NCT04056910 | Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors | completed | Phase 2 | 15 | Jason J. Luke, MDOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06032845 | Cryoablation Combined with Tislelizumab Plus Lenvatinib in Previously Treated Solid Tumors (CASTLE-11)(CASTLE-11) | recruiting | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06173219 | Safety and Efficacy of Radiotherapy Combined with Immunotherapy for Advanced Malignant Tumors. | recruiting | Phase 1 / Phase 2 | 38 | China-Japan Friendship HospitalOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT04785196 | APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 95 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Feb 26, 2025 | clinicaltrials |
| NCT06239155 | A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 51 | Ascentawits Pharmaceuticals, LtdINDUSTRY | 1 | Feb 25, 2025 | clinicaltrials |
| NCT04165330 | Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 56 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT05559541 | Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 33 | AkesoINDUSTRY | 1 | Feb 19, 2025 | clinicaltrials |
| NCT04718675 | A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC) | terminated | Phase 1 / Phase 2 | 135 | Kronos BioINDUSTRY | 3 | Feb 17, 2025 | clinicaltrials |
| NCT05188664 | Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 20 | LaNova Australia Pty LimitedINDUSTRY | 1 | Feb 17, 2025 | clinicaltrials |
| NCT05862324 | TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3)(TACTIC-3) | active not recruiting | Phase 1 / Phase 2 | 113 | Triumvira Immunologics, Inc.INDUSTRY | 2 | Feb 14, 2025 | clinicaltrials |
| NCT05669430 | A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies | recruiting | Phase 1 / Phase 2 | 365 | GV20 TherapeuticsINDUSTRY | 1 | Feb 13, 2025 | clinicaltrials |
| NCT04666688 | LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 44 | PureTechINDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
| NCT06464055 | A Study of GQ1010 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 260 | GeneQuantum Healthcare (Suzhou) Co., Ltd.INDUSTRY | 1 | Feb 10, 2025 | clinicaltrials |
| NCT03213691 | Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 2 | Feb 5, 2025 | clinicaltrials |
| NCT04370834 | Tocilizumab for Patients With Cancer and COVID-19 Disease | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Feb 4, 2025 | clinicaltrials |
| NCT05662397 | A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody | active not recruiting | Phase 1 / Phase 2 | 77 | HotSpot Therapeutics, IncINDUSTRY | 3 | Feb 4, 2025 | clinicaltrials |
| NCT04574583 | Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT) | completed | Phase 1 / Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Feb 3, 2025 | clinicaltrials |
| NCT05497453 | A Phase 1/2 Study to Evaluate OTX-2002 in Patients with Hepatocellular Carcinoma and Other Solid Tumor Types Known for Association with the MYC Oncogene(MYCHELANGELO I) | terminated | Phase 1 / Phase 2 | 24 | Omega TherapeuticsINDUSTRY | 5 | Feb 3, 2025 | clinicaltrials |
| NCT06549946 | Ixovex-1 Single Agent and Combination Therapy(IXACT) | recruiting | Phase 1 / Phase 2 | 18 | Psivac LtdINDUSTRY | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06038396 | A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 48 | RemeGen Co., Ltd.INDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT03220035 | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 2 | Jan 27, 2025 | clinicaltrials |
| NCT05205850 | A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors | recruiting | Phase 1 / Phase 2 | 135 | RemeGen Co., Ltd.INDUSTRY | 1 | Jan 27, 2025 | clinicaltrials |
| NCT06527300 | A Multicenter, Open-label, Single-arm, Phase II Study of NHWD-870 HCl in Adults and Adolescents with Advanced NUT Cancer | unknown | Phase 2 | 48 | Zhejiang Wenda Pharma Technology LTD.INDUSTRY | 1 | Jan 24, 2025 | clinicaltrials |
| NCT06016062 | A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic Malignant Solid Tumors | recruiting | Phase 1 / Phase 2 | 221 | RemeGen Co., Ltd.INDUSTRY | 1 | Jan 23, 2025 | clinicaltrials |
| NCT02240238 | Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer | completed | Phase 1 / Phase 2 | 119 | NanoCarrier Co., Ltd.INDUSTRY | 5 | Jan 22, 2025 | clinicaltrials |
| NCT06764628 | A Study of SHR-4375 in Subjects With Solid Tumors | recruiting | Phase 1 / Phase 2 | 208 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 22, 2025 | clinicaltrials |
| NCT06787950 | Clinical Study of ASN-3186 in Patients with Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 200 | Jiangsu Yahong Meditech Co., Ltd aka AsierisINDUSTRY | 0 | Jan 22, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Apr 3, 2025source: clinicaltrials